Paola Barbarino, CEO of Alzheimer’s Disease International, comments on the role of both international governmental organizations and national governments in addressing the treatment access issues for patients with dementia and Alzheimer’s disease (AD). Ms Barbarino emphasizes the urgent need for governments to understand the scale of the problem, highlighting that many ministers of health fail to comprehend or acknowledge the incidence and prevalence of dementia in their country. Independent organizations, such as Alzheimer’s Disease International (ADI), rely on the generosity of donors, and unfortunately, this is not sufficient to provide the necessary training and diagnostic systems to healthcare professionals (HCPs) and to run public health campaigns on risk reduction. Prioritization of dementia by policy makers is necessary to ensure that patients living with dementia and their families get the care they require. This interview took place at the 18th Annual Congress on Controversies in Neurology (CONy 2024) in London, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
